Stockreport

BioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent Progress

BioAtla, Inc.  (BCAB) 
PDF Ozuriftamab vedotin (CAB-ROR2-ADC) Phase 2 trial in squamous cell carcinoma of the head and neck (SCCHN) continues to demonstrate durable clinical responses and median o [Read more]